RU2005118419A - Вакцина против вируса лихорадки западного нила - Google Patents
Вакцина против вируса лихорадки западного нила Download PDFInfo
- Publication number
- RU2005118419A RU2005118419A RU2005118419/13A RU2005118419A RU2005118419A RU 2005118419 A RU2005118419 A RU 2005118419A RU 2005118419/13 A RU2005118419/13 A RU 2005118419/13A RU 2005118419 A RU2005118419 A RU 2005118419A RU 2005118419 A RU2005118419 A RU 2005118419A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- nucleic acid
- acid molecule
- substitution
- west nile
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 4
- 206010057293 West Nile viral infection Diseases 0.000 title abstract 2
- 201000006449 West Nile encephalitis Diseases 0.000 title 1
- 241000710886 West Nile virus Species 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 6
- 241000710831 Flavivirus Species 0.000 claims abstract 5
- 235000001014 amino acid Nutrition 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 10
- 101710091045 Envelope protein Proteins 0.000 claims 3
- 101710188315 Protein X Proteins 0.000 claims 3
- 102100021696 Syncytin-1 Human genes 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Молекула нуклеиновой кислоты, содержащая последовательности, кодирующие предмембранные и оболочечные белки вируса Западного Нила и капсидные и неструктурные белки вируса желтой лихорадки, где указанный предмембранный или оболочечный белок содержит аттенуирующую мутацию.
2. Молекула нуклеиновой кислоты по п. 1, где указанная аттенуирующая мутация включает аминокислотную замену в положении, выбранном из группы, включающей положения 107, 316 и 440 оболочечного белка.
3. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена находится в положении 107.
4. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена находится в положении 316 и положении 440.
5. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена находится в положениях аминокислот 107, 316 и 440.
6. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена в положении 107 представляет собой замену лейцина на фенилаланин или консервативную аминокислоту.
7. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена в положении 316 представляет собой замену аланина на валин или консервативную аминокислоту.
8. Молекула нуклеиновой кислоты по п. 2, где указанная аминокислотная замена в положении 440 представляет собой замену лизина на аргинин или консервативную аминокислоту.
9. Химерный флавивирус, кодируемый молекулой нуклеиновой кислоты по п. 1.
10. Способ индуцирования иммунного ответа на вирус Западного Нила у субъекта, где указанный способ включает введение субъекту химерного флавивируса по п.9.
11. Способ по п. 10, где указанный субъект подвергается риску развития, но не имеет ее, инфекции, вызываемой вирусом Западного Нила.
12. Способ по п. 10, где указанный субъект инфицирован вирусом Западного Нила.
13. Способ получения химерной флавивирусной вакцины, включающий введение молекулы нуклеиновой кислоты по п. 1 в клетки.
14. Применение химерного флавивируса по п. 9 для вакцинации против вируса Западного Нила.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42659202P | 2002-11-15 | 2002-11-15 | |
| US60/426,592 | 2002-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005118419A true RU2005118419A (ru) | 2006-01-20 |
| RU2376374C2 RU2376374C2 (ru) | 2009-12-20 |
Family
ID=32326380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005118419/13A RU2376374C2 (ru) | 2002-11-15 | 2003-11-13 | Вакцина против вируса лихорадки западного нила |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7507415B2 (ru) |
| EP (1) | EP1575979B1 (ru) |
| JP (1) | JP4683926B2 (ru) |
| KR (1) | KR101150584B1 (ru) |
| AT (1) | ATE452900T1 (ru) |
| AU (1) | AU2003290985B2 (ru) |
| BR (1) | BRPI0316346B1 (ru) |
| CA (1) | CA2505942C (ru) |
| DE (1) | DE60330708D1 (ru) |
| ES (1) | ES2337893T3 (ru) |
| IL (2) | IL168584A (ru) |
| MX (1) | MXPA05005140A (ru) |
| RU (1) | RU2376374C2 (ru) |
| WO (1) | WO2004045529A2 (ru) |
| ZA (1) | ZA200503871B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691550B2 (en) | 2004-10-20 | 2014-04-08 | Sanofi Pasteur Biologics, Llc | Vaccines against japanese encephalitis virus and west nile virus |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7569383B2 (en) | 2001-06-01 | 2009-08-04 | Acambis Inc. | Chimeric flavivirus vectors |
| EP2295023A1 (en) | 2002-01-15 | 2011-03-16 | Sanofi Pasteur Biologics Co. | Flavivirus vaccines |
| US20050002968A1 (en) * | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| AU2003263853A1 (en) * | 2002-08-16 | 2004-03-03 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
| JP4683926B2 (ja) | 2002-11-15 | 2011-05-18 | サノフィ パスツール バイオロジクス カンパニー | ウエストナイルウイルス・ワクチン |
| WO2006029300A2 (en) | 2004-09-09 | 2006-03-16 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
| CA2592005A1 (en) | 2004-12-24 | 2006-06-29 | The Research Foundation For Microbial Diseases Of Osaka University | Attenuated chimeric flavivirus bearing attenuated japanese encephalitis virus gene as backbone |
| RU2465326C2 (ru) | 2005-04-24 | 2012-10-27 | Санофи Пастер Байолоджикс Ко | Рекомбинантные флавивирусные вакцины |
| AU2013204985B2 (en) * | 2005-04-24 | 2016-01-28 | Sanofi Pasteur Biologics, Llc | Recombinant flavivirus vaccines |
| WO2007015783A2 (en) * | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| CL2007003209A1 (es) | 2006-11-07 | 2008-05-09 | Acambis Inc | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion |
| WO2008143713A2 (en) * | 2006-12-22 | 2008-11-27 | Dow Agrosciences Llc | Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences |
| MX2010008799A (es) | 2008-03-05 | 2010-09-07 | Sanofi Pasteur | Proceso para estabilizar una composicion de vacuna que contiene adyuvante. |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| BRPI0918897B1 (pt) | 2008-08-29 | 2021-06-15 | Boehringer Ingelheim Animal Health USA Inc. | Composição imunogênica e seus usos |
| WO2010085358A2 (en) * | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
| CA2770888C (en) * | 2009-08-31 | 2020-04-14 | Gen-Probe Incorporated | Dengue virus assay |
| BR112012024224A2 (pt) * | 2010-03-24 | 2016-11-29 | Arbovax Inc | mutações da faixa de hospedeiro de flavivírus e seu uso. |
| US8889148B2 (en) | 2010-07-01 | 2014-11-18 | Research Development Foundation | Flavivirus host-range mutations and uses thereof |
| MX350718B (es) | 2011-03-14 | 2017-09-14 | Boehringer Ingelheim Vetmedica Inc | Vacuna de rinitis equina. |
| WO2013138670A1 (en) * | 2012-03-15 | 2013-09-19 | Icahn School Of Medicine At Mount Sinai | Yellow fever virus ns5 mutants as flavivirus vaccine candidates |
| US9267114B2 (en) | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| ATE310824T1 (de) | 1991-09-19 | 2005-12-15 | Chimäre und/oder wachstumsgehemmte flaviviren | |
| US6136561A (en) * | 1995-05-24 | 2000-10-24 | Hawaii Biotechnology Group, Inc. | Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| ES2244050T3 (es) | 1997-02-28 | 2005-12-01 | Acambis Inc. | Vacunas quimericas de flavivirus. |
| BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
| US6416763B1 (en) * | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
| WO2001039802A1 (en) | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Chimeric flavivirus vaccines |
| GB2372991B (en) | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
| US7569383B2 (en) | 2001-06-01 | 2009-08-04 | Acambis Inc. | Chimeric flavivirus vectors |
| US6682883B1 (en) * | 2001-07-19 | 2004-01-27 | Acambis, Inc. | Diagnosis of flavivirus infection |
| RU2313367C2 (ru) | 2001-10-19 | 2007-12-27 | Экэмбис, Инк. | Способы профилактики и лечения инфекции, вызываемой флавивирусами у животных |
| DE20120256U1 (de) * | 2001-12-14 | 2002-03-07 | Häfele GmbH & Co., 72202 Nagold | Beschlag |
| EP2295023A1 (en) | 2002-01-15 | 2011-03-16 | Sanofi Pasteur Biologics Co. | Flavivirus vaccines |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| JP4683926B2 (ja) | 2002-11-15 | 2011-05-18 | サノフィ パスツール バイオロジクス カンパニー | ウエストナイルウイルス・ワクチン |
| US7189403B2 (en) | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| WO2005040390A1 (en) | 2003-07-21 | 2005-05-06 | Shanghai Tengen Biomedical Co., Ltd. | A recombinant vaccine using yellow fever virus as vector |
| WO2005049815A1 (en) | 2003-11-21 | 2005-06-02 | K.U.Leuven Research & Development | Flavivirus replication |
| NZ584079A (en) | 2004-10-20 | 2011-10-28 | Acambis Inc | Vaccines against japanese encephalitis virus and west nile virus |
| RU2465326C2 (ru) | 2005-04-24 | 2012-10-27 | Санофи Пастер Байолоджикс Ко | Рекомбинантные флавивирусные вакцины |
| BRPI0504945B8 (pt) | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
-
2003
- 2003-11-13 JP JP2004553787A patent/JP4683926B2/ja not_active Expired - Fee Related
- 2003-11-13 WO PCT/US2003/036623 patent/WO2004045529A2/en not_active Ceased
- 2003-11-13 MX MXPA05005140A patent/MXPA05005140A/es active IP Right Grant
- 2003-11-13 EP EP03783570A patent/EP1575979B1/en not_active Expired - Lifetime
- 2003-11-13 AU AU2003290985A patent/AU2003290985B2/en not_active Ceased
- 2003-11-13 CA CA2505942A patent/CA2505942C/en not_active Expired - Fee Related
- 2003-11-13 DE DE60330708T patent/DE60330708D1/de not_active Expired - Lifetime
- 2003-11-13 KR KR1020057008744A patent/KR101150584B1/ko not_active Expired - Fee Related
- 2003-11-13 AT AT03783570T patent/ATE452900T1/de not_active IP Right Cessation
- 2003-11-13 BR BRPI0316346A patent/BRPI0316346B1/pt not_active IP Right Cessation
- 2003-11-13 ES ES03783570T patent/ES2337893T3/es not_active Expired - Lifetime
- 2003-11-13 RU RU2005118419/13A patent/RU2376374C2/ru not_active IP Right Cessation
- 2003-11-17 US US10/715,868 patent/US7507415B2/en not_active Expired - Fee Related
-
2005
- 2005-05-13 ZA ZA200503871A patent/ZA200503871B/en unknown
- 2005-05-15 IL IL168584A patent/IL168584A/en active IP Right Grant
-
2009
- 2009-03-23 US US12/409,120 patent/US8088391B2/en not_active Expired - Fee Related
- 2009-12-27 IL IL202978A patent/IL202978A/en active IP Right Grant
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691550B2 (en) | 2004-10-20 | 2014-04-08 | Sanofi Pasteur Biologics, Llc | Vaccines against japanese encephalitis virus and west nile virus |
Also Published As
| Publication number | Publication date |
|---|---|
| US8088391B2 (en) | 2012-01-03 |
| IL202978A (en) | 2013-11-28 |
| DE60330708D1 (de) | 2010-02-04 |
| US20050053624A1 (en) | 2005-03-10 |
| AU2003290985B2 (en) | 2010-04-01 |
| JP4683926B2 (ja) | 2011-05-18 |
| ES2337893T3 (es) | 2010-04-30 |
| US20070275015A9 (en) | 2007-11-29 |
| KR20050072143A (ko) | 2005-07-08 |
| KR101150584B1 (ko) | 2012-06-27 |
| WO2004045529A3 (en) | 2004-08-26 |
| EP1575979A4 (en) | 2006-06-21 |
| ZA200503871B (en) | 2006-08-30 |
| US20100086564A1 (en) | 2010-04-08 |
| CA2505942C (en) | 2012-03-13 |
| EP1575979A2 (en) | 2005-09-21 |
| IL168584A (en) | 2010-12-30 |
| IL202978A0 (en) | 2011-08-01 |
| US7507415B2 (en) | 2009-03-24 |
| ATE452900T1 (de) | 2010-01-15 |
| EP1575979B1 (en) | 2009-12-23 |
| BR0316346A (pt) | 2005-09-27 |
| MXPA05005140A (es) | 2005-08-19 |
| RU2376374C2 (ru) | 2009-12-20 |
| JP2006506092A (ja) | 2006-02-23 |
| HK1083192A1 (en) | 2006-06-30 |
| AU2003290985A1 (en) | 2004-06-15 |
| BRPI0316346B1 (pt) | 2016-05-31 |
| WO2004045529A2 (en) | 2004-06-03 |
| CA2505942A1 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005118419A (ru) | Вакцина против вируса лихорадки западного нила | |
| ES2757927T3 (es) | Virus de la peste porcina clásica (VPPC) recombinante que comprende sustituciones en el epítopo TAV de la proteína E2 | |
| JP2012061001A (ja) | 弱毒ペスチウイルスを含むワクチン | |
| CN101670101A (zh) | 减毒的活疫苗 | |
| US9878031B2 (en) | Compositions, methods of administration and uses for trivalent dengue virus formulations | |
| AR041964A1 (es) | Vacuna de vhc que comprende un polinucleotido | |
| WO2012038454A1 (en) | Bvdv vaccine | |
| US20230149528A1 (en) | Development of mosaic vaccines against foot and mouth disease virus serotype o | |
| ES2644801T3 (es) | Antígenos de vacuna quimérica contra el virus de la hepatitis c | |
| BR0112020A (pt) | Partìculas tipo vìrus de bvdv | |
| CN115927416B (zh) | 嵌合猪瘟病毒、猪瘟标记疫苗及其制备方法和应用 | |
| KR100902197B1 (ko) | 티모신에 의한 유전적 면역화 증대 | |
| WO2023006131A1 (es) | Antigeno recombinante para la induccion de respuesta inmune contra el virus zika | |
| Yokosuka et al. | High detection rate of hepatitis C virus E2 antibody in patients with type C hepatitis | |
| WO2007103565A2 (en) | Wnv dna vaccine incorporating a cmv/r backbone and expressing wnv prm and e proteins | |
| Shahana et al. | Enhancement of Japanese Encephalitis Virus DNA vaccine efficacy by using Mycobacterium avium paratuberculosis heat shock protein 65 | |
| HK1083192B (en) | West nile virus vaccine | |
| RU2007108290A (ru) | Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181114 |